Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Sentimental tree to shine at Arctic League annual broadcast - 2A somber Thor is returning for 'Avengers: Doomsday': Watch the dread-filled teaser
- 3Astronomers detect black hole blasting winds at incredible speeds
- 4The most effective method to Examine a Cellular breakdown in the lungs Finding with Family
- 5Indian Health Service is digging out of decades-old construction backlog for medical buildings
- CDC clarifies stance on vaccines and autism, stating no evidence supports the link
- 6 Asian Urban areas to Visit
- Deadly Switzerland ski resort fire was likely started by sparklers attached to champagne bottles, officials say
- Winter virus season so far is not too bad, but doctors worry about suffering to come
- Sea level doesn’t rise at the same rate everywhere – we mapped where Antarctica’s ice melt would have the biggest impact
- 6 Modest and Strong Tire Brands
- Our favorite Space.com stories of 2025
- NASA chief Jared Isaacman says Texas may get a moonship, not space shuttle Discovery
- Watch live as near-Earth asteroid Eros buzzes the Andromeda Galaxy on Nov. 30 (video)
